About SCIENTECH Company

Lepuxintai Medical Technology (Shanghai) Co., Ltd. is committed to providing safe, effective and innovative medical solutions. It is a pioneer in the structural cardiac interventional medical device industry in China and the largest domestic supplier of congenital heart disease blocking devices. Focus on R&D, production and marketing of structural heart disease medical interventional devices. Currently, there are 50 products on the market and under development. The product line covers the congenital occluder series for interventional treatment of congenital heart disease, the left atrial occlusion device series for the prevention of cardiogenic stroke, and the biointerventional valve series for the treatment of valve stenosis and incomplete closure, etc., which can provide comprehensive solutions for interventional treatment of structural heart disease. Our products have been sold overseas to 44 countries and regions in Asia, Europe, America and Africa. The company has strong R&D strength, has a number of innovative products with independent intellectual property rights, and first participated in the research and development of biodegradable technology. In 2009, the “Development and Clinical Application of a Series of Blockers and Related Devices for Interventional Treatment of Defective Congenital Heart Disease” project won the second prize of the National Science and Technology Progress Award. As of October 18, 2022, the company has 232 registered intellectual property rights. In the future, the company will continue to invest in research and development, continuously develop new products and technologies, benefit more patients with structural heart disease, and contribute to the cause of human health.